The estimated Net Worth of Michael S Klein is at least 676 千$ dollars as of 8 December 2021. Mr Klein owns over 13,475 units of Icad Inc stock worth over 55,332$ and over the last 14 years he sold ICAD stock worth over 0$. In addition, he makes 621,021$ as Exec. Chairman & CEO at Icad Inc.
Mr has made over 1 trades of the Icad Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he bought 13,475 units of ICAD stock worth 99,446$ on 8 December 2021.
The largest trade he's ever made was buying 13,475 units of Icad Inc stock on 8 December 2021 worth over 99,446$. On average, Mr trades about 561 units every 0 days since 2010. As of 8 December 2021 he still owns at least 39,807 units of Icad Inc stock.
You can see the complete history of Mr Klein stock trades at the bottom of the page.
Michael S. Klein is the Exec. Chairman & CEO at Icad Inc.
As the Exec. Chairman & CEO of Icad Inc, the total compensation of Mr Klein at Icad Inc is 621,021$. There are no executives at Icad Inc getting paid more.
Mr Klein is 67, he's been the Exec. Chairman & CEO of Icad Inc since . There are no older and 11 younger executives at Icad Inc.
Michael's mailing address filed with the SEC is C/O ICAD, INC., 98 SPIT BROOK ROAD, SUITE 100, NASHUA, NH, 03062.
Over the last 22 years, insiders at Icad Inc have traded over 10,970,060$ worth of Icad Inc stock and bought 704,596 units worth 1,672,448$ . The most active insiders traders include Anthony F Ecock、Nathaniel Dalton、Kevin C Burns. On average, Icad Inc executives and independent directors trade stock every 45 days with the average trade being worth of 39,056$. The most recent stock trade was executed by Dana R Brown on 31 March 2023, trading 40,000 units of ICAD stock currently worth 52,000$.
icad is a leading provider of advanced image analysis, workflow solutions and radiation therapies for the early identification and treatment of common cancers. icad offers a comprehensive range of high-performance, upgradeable cad solutions for mammography and advanced image analysis and workflow solutions for magnetic resonance imaging, for breast and prostate cancers and computed tomography for colorectal cancer. icad’s xoft system, offers radiation treatment for early-stage breast cancer that can be administered in the form of intraoperative radiation therapy or accelerated partial breast irradiation. the xoft system is also cleared for the treatment of non-melanoma skin cancer and endometrial cancer. for more information, call 877-icadnow, or visit www.icadmed.com.
Icad Inc executives and other stock owners filed with the SEC include: